Clariant

Clariant optimistic for Q4 2026

03/11/26 -"Clariant’s Q3 2026 growth was price-led, though underlying volumes improved in Care Chemicals and A&A. Middle East conflict weighed on Catalysts. Margins fell on a non-recurring corporate phasing ..."

PDF page sample
Pages
52
Language
English
Published on
03/11/26
Download
You may also be interested by these reports :
03/11/26
Clariant’s Q3 2026 growth was price-led, though underlying volumes improved in Care Chemicals and A&A. Middle East conflict weighed on Catalysts. ...
02/11/26
Fuchs reported a strong but price-led Q3 2026, a shift from volume-led Q2 2026. EBIT recorded its all-time high as supply constraints pushed prices. ...
30/10/26
Following preliminary Q3 results announced earlier, Fuchs confirmed strong sales and EBIT growth of 25% and 27%, respectively. However, organic ...
29/10/26
Wacker’s Q3 2026 sales growth was price-led, reflecting cost pass-through rather than a recovery in demand. The chemicals divisions led earnings, ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO